These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Prion protein and the molecular features of transmissible spongiform encephalopathy agents. Silveira JR; Caughey B; Baron GS Curr Top Microbiol Immunol; 2004; 284():1-50. PubMed ID: 15148986 [TBL] [Abstract][Full Text] [Related]
44. The pathogenic mechanisms of prion diseases. Hur K; Kim JI; Choi SI; Choi EK; Carp RI; Kim YS Mech Ageing Dev; 2002 Nov; 123(12):1637-47. PubMed ID: 12470901 [TBL] [Abstract][Full Text] [Related]
45. Transmission and Replication of Prions. Marín-Moreno A; Fernández-Borges N; Espinosa JC; Andréoletti O; Torres JM Prog Mol Biol Transl Sci; 2017; 150():181-201. PubMed ID: 28838661 [TBL] [Abstract][Full Text] [Related]
46. Thienyl pyrimidine derivatives with PrP(Sc) oligomer-inducing activity are a promising tool to study prions. Imberdis T; Ayrolles-Torro A; Verdier JM; Perrier V Curr Top Med Chem; 2013; 13(19):2477-83. PubMed ID: 24059332 [TBL] [Abstract][Full Text] [Related]
47. Prions and their partners in crime. Caughey B; Baron GS Nature; 2006 Oct; 443(7113):803-10. PubMed ID: 17051207 [TBL] [Abstract][Full Text] [Related]
48. Introduction to Current Progress in Advanced Research on Prions. Onodera T; Sakudo A Curr Issues Mol Biol; 2020; 36():63-66. PubMed ID: 31559970 [TBL] [Abstract][Full Text] [Related]
49. Molecular aspects of disease pathogenesis in the transmissible spongiform encephalopathies. Priola SA; Vorberg I Mol Biotechnol; 2006 May; 33(1):71-88. PubMed ID: 16691009 [TBL] [Abstract][Full Text] [Related]
51. Neurodegeneration in humans caused by prions. Prusiner SB West J Med; 1994 Sep; 161(3):264-72. PubMed ID: 7975565 [TBL] [Abstract][Full Text] [Related]
52. Porcine prion protein amyloid. Hammarström P; Nyström S Prion; 2015; 9(4):266-77. PubMed ID: 26218890 [TBL] [Abstract][Full Text] [Related]
53. Creutzfeldt-Jakob disease and mad cows: lessons learnt from yeast cells. Hofmann J; Wolf H; Grassmann A; Arndt V; Graham J; Vorberg I Swiss Med Wkly; 2012; 142():w13505. PubMed ID: 22270552 [TBL] [Abstract][Full Text] [Related]
54. A survey and a molecular dynamics study on the (central) hydrophobic region of prion proteins. Zhang J; Wang F Curr Pharm Biotechnol; 2014; 15(11):1026-48. PubMed ID: 25373387 [TBL] [Abstract][Full Text] [Related]
55. Prion protein misfolding and disease. Moore RA; Taubner LM; Priola SA Curr Opin Struct Biol; 2009 Feb; 19(1):14-22. PubMed ID: 19157856 [TBL] [Abstract][Full Text] [Related]
56. Molecular mechanisms of neurotoxicity of pathological prion protein. Castilla J; Hetz C; Soto C Curr Mol Med; 2004 Jun; 4(4):397-403. PubMed ID: 15354870 [TBL] [Abstract][Full Text] [Related]
57. Prion diseases: what is the neurotoxic molecule? Chiesa R; Harris DA Neurobiol Dis; 2001 Oct; 8(5):743-63. PubMed ID: 11592845 [TBL] [Abstract][Full Text] [Related]
58. [Amyloidgenesis in prion disease]. Tsuboi Y Brain Nerve; 2014 Jul; 66(7):849-55. PubMed ID: 24998829 [TBL] [Abstract][Full Text] [Related]
59. Getting a grip on prions: oligomers, amyloids, and pathological membrane interactions. Caughey B; Baron GS; Chesebro B; Jeffrey M Annu Rev Biochem; 2009; 78():177-204. PubMed ID: 19231987 [TBL] [Abstract][Full Text] [Related]
60. The Structure of Mammalian Prions and Their Aggregates. Vázquez-Fernández E; Young HS; Requena JR; Wille H Int Rev Cell Mol Biol; 2017; 329():277-301. PubMed ID: 28109330 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]